GHRP-6 & GHRP-2
$Older GH secretagogues; Real endocrine effect with higher side-effect burden
GHRP-2 and GHRP-6 are ghrelin-receptor agonists that stimulate growth-hormone release. They can also affect hunger, prolactin, cortisol, glucose, and water retention.
The endocrine mechanism is real, but these compounds are not FDA-approved wellness therapies. They are less selective than ipamorelin and carry anti-doping and compounding concerns. Understand pulse dynamics: the goal is a GH pulse, not a constant drug level. Watch for desensitization, glucose changes, prolactin/cortisol spillover, edema, and appetite effects.
Classification details
- GHRP-2 and GHRP-6 are synthetic growth-hormone-releasing peptides in the older growth-hormone secretagogue family.
- They act at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a.
- GHRP-2 and GHRP-6 are ghrelin/GHS-R agonist secretagogues, not GHRH analogs. They are often grouped, but hunger, cortisol/prolactin spillover, and potency can differ.
- Both compounds trigger pituitary GH release and interact with hypothalamic-pituitary regulation.
- GHRP-6 is more strongly associated with hunger stimulation.
- GHRP-2 is generally described as less appetite-provoking but still less selective than ipamorelin.
- The GH pulse is also shaped by sleep, nutrition, blood glucose, free fatty acids, somatostatin tone, endogenous GHRH, age, adiposity, and prior secretagogue exposure.
- That is why response varies and why repeated stimulation can lose effect.
- They stimulate GH release through GHS-R and work best conceptually when pituitary GH reserve exists. GHRP-6 is more hunger-promoting. GHRP-2 is often described as stronger GH-releasing but less selective than ipamorelin.